Benefits of running first-in-human and vaccine studies in Australia – Novotech webinar

The leading Asia-Pacific biotech specialist CRO Novotech is collaborating with biotech and pharma news platform Endpoints News for a webinar about the strategic and quality benefits of running first-in-human and vaccine studies in Australia.

Novotech has conducted over 500 early phase clinical trials for biotech companies.

According to Novotech:

“The regulatory environment in Australia offers a significant strategic opportunity for international biotech companies who can take advantage of a uniquely fast and pragmatic regulatory pathway for early phase clinical trials.

A US Investigational New Drug (IND) submission is not necessary to initiate first-in-human clinical trials in Australia.

The rapid Australian and New Zealand regulatory and ethics processes often means biotech companies can initiate their clinical programs and commence dosing within a single review cycle of 6-8 weeks from submission.

As a result, many biotechnology companies can commence a first-in-human clinical trial in parallel to the preparation of a US IND submission.”

During this webinar, experts will discuss:

• The latest research and trends of early phase clinical trials globally and in Asia-Pacific, with a focus on vaccine studies

• How the Australian regulatory requirement compares with the US, and what are the benefits for biotechnology companies to involve sites in Australia

• How to take advantage of the Australian R&D Government refund (of up to 43.5%)

• Feedback from sponsors and investigators

The webinar will be led by Endpoints News Publisher Arsalan Arif. Participants will include leading experts from the Australian clinical trial sector:

• Dr. Paul Griffin, Principal Investigator at Nucleus Network

• Dr. Jeff Loutit, Chief Medical Officer at Qpex Biopharma

• Dr. Simone Flight, Senior Consultant at Novotech Biodesk

• Stewart Walker, President, CoSec USA

Webinar: Running First-in-human and Vaccine Studies in Australia

Broadcast time: August 11, 2-3pm EDT

Click here to register https://webinars.endpts.com/running-first-in-human-and-vaccines-studies-in-australia/

Novotech has teams on the ground in the key Asia-Pacific countries and has just signed its 30th Partnership agreement which is a program with leading medical institutions throughout the Asia-Pacific giving Novotech clients unique access to some of the top researchers, investigators and key opinion leaders.

###

David James

[email protected]

AU: +61 2 8218 2144

USA: +1 415 951 3228

Asia: +65 3159 3427

About Novotech – https://novotech-cro.com?Novotech is internationally recognized as the leading regional full-service contract research organization (CRO) in Asia-Pacific. Novotech has been instrumental in the success of over a thousand Phase I – IV clinical trials for biotechnology companies. ?

Novotech was established in 1996, with offices in 11 locations across the region, and site partnerships with major health institutions.
 

Novotech provides clinical development services across all clinical trial phases and therapeutic areas including: feasibility assessments; ethics committee and regulatory submissions, data management, statistical analysis, medical monitoring, safety services, central lab services, report write-up to ICH requirements, project and vendor management. Novotech obtained the ISO 27001 certification which is the best-known standard in the ISO family providing requirements for an Information Security Management System. Together with the ISO 9001 Quality Management system, Novotech aims at the highest IT security and quality standards for patients and biotechnology companies.  
 

For RFP enquiries: Please fill out the form available at https://novotech-cro.com/talk-to-an-expert